MilliporeSigma Announces Increased Commercial Capacity in France as Part of New Millipore® CTDMO Services

  • New 2,700 Square Meter Facility Increases Capacity for Production of Monoclonal Antibodies (mAb) and Other Recombinant Proteins

  • Customers benefit from differentiated CTDMO services that simplify the experience to speed time to market

  • End-to-end support through clinical and late-stage commercialization further accelerates and streamlines the drug development process; one of the company’s “Big 3” growth engines

BURLINGTON, Mass., October 4, 2022 /PRNewswire/ — MilliporeSigma, the U.S. and Canadian life sciences business of Merck KGaA, Darmstadt, Germanya leading science and technology company, today announced that its Life Science business has opened a commercial facility for its new Millipore® CTDMO service offer on the company’s site in Martillac, France. The 2,700 square meter facility will provide a global supply of commercial drug substances, including mAbs and other recombinant proteins, from an integrated site with state-of-the-art single-use equipment and regulatory experts, quality and techniques on site.

New commercial installation of MilliporeSigma for its Millipore® CTDMO service offering at the company’s site in Martillac, France. MilliporeSigma is the US and Canadian life sciences arm of Merck KGaA, Darmstadt, Germany.

“Our customers are the pioneers of modern medicine and manage multiple partners, supply chain needs and complex priorities and look to our company to help them navigate complexity and provide flexibility and scalability,” said Dirk LangeHead of Life Science Services, Life Science business area of ​​Merck KGaA, Darmstadt, Germany. “With this facility and our global Millipore® CTDMO Service Network, we offer truly differentiated services, including models for drug development, manufacturing and commercialization to accelerate molecules to market with an experienced partner.”

This expansion will support customers such as Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company specializing in pediatric immunotherapies leveraging the company’s CTDMO services. “With support from the life sciences industry, we got our pediatric brain cancer product candidate to patients in about half the time of the approximately 12 years it typically takes to get a biologic on the market. market,” said Torben Lund Hansen, CTO, Technical Operations Manager, Y-mAbs. “Their end-to-end process development and GMP-compliant manufacturing services were key to reaching this milestone.”

The Martillac facility is designed to operate at the highest level of efficiency and can quickly scale from 200 to 2,000 liters of drug substance. It also includes two 2,000 liter bioreactors in a single manufacturing suite to increase capacity and flexibility. Using state-of-the-art technology and a proven quality system enables life science customers to streamline and accelerate the process to market by eliminating the need for technology transfer and upgrades. scale between clinical and commercial stages. This differentiated CTDMO service offering is purpose-built and seamlessly integrates product characterization and safety testing to accelerate the development and commercialization process.

With more than 30 years of expertise in drug development, materials science and process technology, Millipore® CTDMO’s service offerings span from preclinical to commercial phases, including testing, across multiple modalities, including mAbs, high potency active pharmaceutical ingredients, antibody-drug conjugates, viral vector therapies, l mRNA and the formulation of lipid nanoparticles. This includes hardware and software, single-use consumables and raw materials. The company’s network includes sites across Europethe United States and Asia.

The Millipore company® CTDMO Services is part of the recently created Life Science Services business unit, which together with the Process Solutions business is one of its “Big 3” growth drivers. The company aims to increase its group sales to approximately 25 billion euros by 2025. To achieve its growth objectives, the company plans to increase its total investments between 2021 and 2025 significantly compared to in the period 2016-2020.

Recently, the company announced plans for expansion in its life sciences business by Verona and Sheboygan, Wis.UNITED STATES; Cork, Ireland; Wuxi, China; Darmstadt, Germany; Logs, Swiss; Carlsbad, CaliforniaUNITED STATES; Jaffrey, New Hampshire, UNITED STATES; and Danvers, Mass.United States, Molsheim, Franceand Shanghai, China. These expansions are part of an ambitious multi-year program to increase the capacity and capabilities of the company’s life sciences business to meet growing global demand for lifesaving medicines and make a significant contribution to public health.

For more information about the company’s Millipore® CTDMO services, visit

About the Life Sciences business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germanywhich operates as MilliporeSigma in the United States and Canada, has more than 26,000 employees and more than 55 manufacturing and test sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germanya leading science and technology company, operates in healthcare, life sciences and electronics.

Approximately 60,000 employees work every day to make a positive difference in the lives of millions of people by creating more joyful and sustainable lifestyles. From advancing gene-editing technologies and discovering unique ways to treat the toughest diseases to enabling device intelligence, the company is everywhere. In 2021, Merck KGaA, Darmstadt, Germany generated a turnover of 19.7 billion euros in 66 countries.

The company owns the global rights to the “Merck” name and trademark internationally. The only exceptions are United States and Canadawhere the business areas of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life sciences and EMD Electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been at the heart of the company’s technological and scientific advancements. To this day, the founding family remains the majority shareholder of the listed company. For more information about Merck KGaA, Darmstadt, Germanyvisit

Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.

All Merck KGaA, Darmstadt, Germany press releases are distributed by e-mail as soon as they are available on the EMD Group website. If you reside in the United States or Canada please go to to re-register for your online subscription to this service, as our new geo-targeting requires new links in the email. You can later change your selection or discontinue this service.



See original content to download multimedia: -ctdmo-services-301639759.html



Comments are closed.